Freestone Capital Holdings LLC Sells 32,133 Shares of Novo Nordisk A/S $NVO

Key Points

• Freestone Capital Holdings LLC cut its stake in Novo Nordisk by 56.3%, selling 32,133 shares in Q4 and leaving 24,924 shares worth about $1.27 million.
• Novo Nordisk announced a strategic partnership to embed OpenAI across discovery, manufacturing and commercial teams and is running a DKK 15bn share repurchase programme, actions seen as boosting R&D momentum and supporting the stock.
• Despite those positives, analysts have trimmed targets after weaker Wegovy prescription data and competition from Eli Lilly’s new oral obesity pill (Foundayo) is increasing pricing and market‑share risks for Novo’s GLP‑1 franchise.

Freestone Capital Holdings LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 56.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,924 shares of the company's stock after selling 32,133 shares during the quarter. Freestone Capital Holdings LLC's holdings in Novo Nordisk A/S were worth $1,268,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in NVO. Revolve Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after acquiring an additional 200 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 21.0% during the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company's stock worth $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company's stock worth $712,000 after acquiring an additional 1,587 shares in the last quarter. Invesco Ltd. grew its stake in shares of Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company's stock worth $28,967,000 after acquiring an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL bought a new position in shares of Novo Nordisk A/S during the 2nd quarter worth approximately $314,000. 11.54% of the stock is owned by institutional investors.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Strategic OpenAI partnership — Novo Nordisk says it will embed OpenAI’s advanced AI across discovery, manufacturing and commercial teams to accelerate candidate identification and shorten time to market, a development investors see as restoring R&D momentum and helping find "the next Ozempic." Novo Nordisk and OpenAI Partner to Speed Drug Discovery
• Positive Sentiment: Share buyback in place — Novo Nordisk has an active repurchase programme (part of a DKK 15bn plan) that supports demand for stock and signals management confidence in cash flow generation. Novo Nordisk A/S - share repurchase programme
• Neutral Sentiment: Sector/market backdrop — U.S. trading in European ADRs and a modestly stronger healthcare sector provided supportive market conditions for Novo’s ADRs today, amplifying headline-driven moves. European Equities Traded in the US as ADRs Rise in Tuesday Trading
• Negative Sentiment: Wall Street price‑target resets after weaker Wegovy script data — Analysts have trimmed targets and flagged disappointing prescription trends for Wegovy, which pressures near‑term revenue and sentiment. Wall Street Resets Novo Nordisk Price Target
• Negative Sentiment: Rising competitive pressure — Eli Lilly’s new oral obesity pill (Foundayo) and other entrants are intensifying competition in the weight‑loss market, creating pricing and market‑share risks for Novo’s GLP‑1 franchise. Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
• Negative Sentiment: Institutional selling / outlook concerns — The Vltava Fund disclosed selling NVO citing fears of a deteriorating financial outlook, a sign that some investors remain worried about near‑term growth and guidance. Vltava Fund Sold Novo Nordisk (NVO) on Fear of Deteriorating Financial Outlook

Analyst Ratings Changes

Several equities analysts have recently weighed in on NVO shares. Jefferies Financial Group raised shares of Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a research note on Thursday, February 12th. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Morgan Stanley raised shares of Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target for the company in a research note on Tuesday, March 3rd. CICC Research initiated coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an "outperform" rating and a $73.50 price objective for the company. Finally, BMO Capital Markets reissued a "market perform" rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Four research analysts have rated the stock with a Buy rating and twenty have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $65.56.

Novo Nordisk A/S Trading Up 3.6%

NYSE NVO opened at $39.33 on Wednesday. The company has a market cap of $175.61 billion, a PE ratio of 11.33, a PEG ratio of 8.96 and a beta of 0.73. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44. The stock has a 50 day moving average of $40.39 and a 200-day moving average of $48.67.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were issued a dividend of $1.2751 per share. The ex-dividend date of this dividend was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 50.43%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.